{"id":"elixcyte","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ELIXCYTE involves ex vivo expansion of patient-derived immune cells, likely T cells or natural killer cells, which are then reinfused to boost the body's ability to recognize and eliminate cancer cells. This approach leverages the patient's own immune system without genetic modification, aiming to provide durable anti-tumor responses.","oneSentence":"ELIXCYTE is an autologous cell therapy that expands and reinfuses a patient's own immune cells to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:38.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05526001","phase":"PHASE3","title":"Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UnicoCell Biomed CO. LTD","startDate":"2023-07-03","conditions":"Knee Osteoarthritis","enrollment":165},{"nctId":"NCT02933827","phase":"PHASE1, PHASE2","title":"Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease","status":"COMPLETED","sponsor":"UnicoCell Biomed CO. LTD","startDate":"2018-05-01","conditions":"Moderate to Severe Chronic Kidney Disease","enrollment":39},{"nctId":"NCT02784964","phase":"PHASE1, PHASE2","title":"Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis","status":"COMPLETED","sponsor":"UnicoCell Biomed CO. LTD","startDate":"2016-03","conditions":"Knee Osteoarthritis","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ELIXCYTE","genericName":"ELIXCYTE","companyName":"UnicoCell Biomed CO. LTD","companyId":"unicocell-biomed-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ELIXCYTE is an autologous cell therapy that expands and reinfuses a patient's own immune cells to enhance anti-tumor immunity. Used for Solid tumors (specific indications under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}